A Randomized Phase II Study of Erlotinib Plus Nab-Paclitaxel Versus Erlotinib Alone as Second-Line Therapy for Chinese Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer

查看全文 作　　者：Yong;Zhang;Chao;Gao;Wei;Qu;Yongsheng;Gao;Shouhui;Zhu;Shuo;Zhang;Wei;He;Yonghua;Yu 出　　处：《Cancer Investigation》索引2015年,共0页